Counteracting muscle wasting in aging and neuromuscular diseases:






































It is generally accepted that the primary cause of 
functional impairment in muscle is a cumulative failure 
to repair damage related to an overall decrease in 
anabolic processes. Despite numerous theories and 
intensive research, the principal molecular mechanisms 
underlying the process of muscle wasting are still 
unknown.  
 
Current data point out that muscle wasting is a 
multifactorial process and believed to be the result of 
both intrinsic factors, involving changes in molecular 
and cellular levels, and extrinsic ones, such as nutrition 
and exercise [1]. Among intrinsic factors, the proteolytic 
systems have been postulated to be responsible for the 



































































mediated protein degradation are the principal 
proteolytic pathways activated in several pathologies, 
leading to myofiber degeneration, and impaired muscle 
regeneration.  
 
Calpains are calcium-activated cysteine proteases that 
participate in various intracellular signal transduction 
pathways mediated by Ca
2+ [2], causing disruption of 
the contractile tissue, mitochondrial swelling, 
sarcoplasmic reticulum vacuolization, and sarcomeric 
alterations.  
 
The ubiquitin-proteasome pathway plays a key role in 
the turnover of muscle protein and the pathway involves 
an enzymatic cascade starting with the ubiquitination of 
muscle protein to be degraded by the 26S proteasome in 
a process that unfolds the protein, releases ubiquitin, 
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acids [3].  
 
Caspases are a family of cysteine proteases, 
representing central components of the apoptotic 
machinery in several tissues [4]. 
 
Additionally, many other factors, including stress 
oxidative damage and alteration in satellite cells activity 
may all contribute to muscle wasting [5, 6].  
 
In designing therapies that can counteract muscle wasting 
it is important to choose molecules able to maintain 
muscle mass, suppress muscle loss and stimulate muscle 
regeneration. In this context, one of the potential 
candidates is the insulin-like growth factor-1 (IGF-1), 
involved in several anabolic process in skeletal muscle 
[7]. 
 
The molecular complexities of IGF-1 transcription  
 
An impressive body of knowledge has been accumulated 
since the IGF-1 locus was first described, but surprisingly 
the potential diversity of roles played by different IGF-1 
isoforms has only recently been appreciated. As its name 
implies, IGF-1 is similar to insulin in structure, with it 
shares a 50% amino acid identity. However, unlike the 
insulin gene, the single-copy IGF-1 gene locus encodes 
multiple proteins with variable amino- and carboxy-
terminal amino acid sequences (Figure 1). The amino 
acid sequence of the mature peptide differs from that of 
insulin by retention of the C peptide, by a short extension 
of the A chain to include a novel domain D, and by the 





















Although the IGF-1 gene is highly conserved in 
numerous species, its relatively large size (>70 kb), and 
its complex transcriptional and splicing pattern, have 
complicated its analysis. 
 
The rodent IGF-1 gene contains six exons, separated by 
five introns (Figure 1) [8]. Exons 1 and 2 encode 
distinct 5´UTRs, as well as different parts of the signal 
peptide, and are therefore termed leader exons. Exon 3 
encodes 27 amino acids that are part of the signal 
peptide and common to all isoforms, as well as part of 
the mature IGF-1 peptide. 
 
Exon 4 encodes the rest of the mature peptide and 16 
amino acids of the amino-terminal region of the E-
peptide, which is also common to all IGF-1 mRNAs. 
Exons 5 and 6 encode two distinct carboxy-terminal E-
peptides and the 3´UTR. 
 
Although IGF-1 transcripts are not exclusively tissue-
restricted, those that initiate at Exon 2 predominate in 
the liver, are highly growth hormone responsive and as 
such are major endocrine effectors of GH [9]. By 
contrast, transcripts initiating at Exon 1 are widely 
expressed in all tissues, and are less effected by 
circulating growth hormone levels, presumably 
performing autocrine or paracrine functions. The 
alternate splicing at the 5’ ends of these two IGF-1 
transcripts generates different signal peptides, which 
purportedly affects the precise N-terminal pro-peptide 
cleavage site [9]. The function of the proteins encoded 
by these different transcripts is widely debated but a 
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alternate splicing at the 3’ end of IGF-1 transcripts. This 
produces variability in the length and amino acid 
sequence of the E peptide, and in the length and base 
sequence of the 3’UTR. To date, two different splice 
patterns have been documented in rodents (Figure 1). 
Each generates E peptides with a common N-terminal 
16 aa sequence, and alternate C-terminal sequences [8, 
11]. If Exon 4 splices to Exon 6 (the predominant 
pattern), the length of the 3’UTR is highly variable, but 
in all cases the Ea peptide is generated with 19 
additional amino acids. If Exon 4 splices to Exon 5 and 
6, a variant known as Eb is encoded, which is 
frameshifted relative to Exon 6 and therefore a different 
25 aa sequence is added to the common 16 aa encoded 
by Exon 4.  
 
Although E peptide choice appears to be independent of 
promoter use, Eb-containing transcripts are more 
abundant in liver, whereas Ea-containing transcripts are 
widespread in extra-hepatic tissues. In addition, the 
analysis of the amino acid structure of both E-peptides 
has revealed the presence of two N-linked glycosylation 
sites only in the Ea peptide, but not in the Eb peptide, 
suggesting that this post-translational modification is 
involved in a biological action of the IGF-1 isoform 
[11]. 
 
The IGF-1Eb isoform is also up-regulated in muscles 
subjected to stretch and has been named mechano 
growth factor (MGF) [12]. The determination of E 
peptide function and fate awaits the availability of 
epitope-specific antibodies, since it is unclear when or 
whether E peptides are cleaved from the mature IGF-1 
protein. Notably, E peptide splicing patterns are 
different in the human gene [8], an anomaly that will 
need to be considered in the future when translating the 
results of animal research into clinical applications. 
 
The importance of IGF-1 isoforms 
 
Analyses of transgenic mice expressing different IGF-1 
isoforms have provided insight into the role of IGF-1 
signaling in the physiology of striated muscle [7]. The 
fact that IGF-1 can act either as a circulating hormone 
or as a local growth factor has confounded previous 
analyses of animal models in which transgenic IGF-1 
synthesized in extra-hepatic tissues was released into 
the circulation. Thus, over-expression of one IGF-1 
isoform in the heart prevented activation of cell death in 
the viable myocardium after infarction, limiting 
ventricular dilation, myocardial loading, cardiac 
hypertrophy, and diabetic cardiomyopathy, supporting 
the notion that constitutive over-expression of IGF-1 in 
cardiomyocytes protects them from apoptosis and 
hypertrophy in the normal and pathological heart [13, 
14]. However, in another study, over-expression of a 
different IGF-1-transgene in the heart induced 
physiological cardiac hypertrophy that progressed to 
maladaptive hypertrophy [15]. The discrepancies in 
these phenotypes underscore the normal physiological 
difference between IGF-1 isoform function. In addition, 
substantial evidence supports the involvement of IGF-1 
in mitogenesis and neoplastic transformation [16], 
suggesting that this signaling pathway plays an 
important role in the process of tumor promotion. The 
neoplastic potential of at least certain IGF-1 isoforms is 
an obvious concern to be taken into account when 
designing IGF-therapeutic strategies for human 
pathologies, where the specific role of each IGF-1 
isoform must be viewed in the appropriate tissue 
context. 
 
Thus, restricting the action of supplemental IGF-1 to the 
tissue of origin by use of a local IGF-1 isoform will 
allow the assessment of its autocrine/paracrine role in 
skeletal muscle throughout the life-span of the animal, 
exclusive of possible endocrine effects on other tissues. 
 
The effects of local isoform of IGF-1 on muscle 
homeostasis 
 
mIGF-1 and muscle aging 
The prolongation of skeletal muscle strength in aging 
and neuromuscular disease has been the objective of 
numerous studies employing a variety of approaches. 
 
IGF-1, involved in muscle growth and hypertrophy, 
decline during postnatal life, raising the prospect that 
this decline contributes to the progress of muscle 
atrophy in senescence, and limits the ability of skeletal 
muscle tissue to effect repair or to regenerate. 
 
To test this possibility we generated a transgenic mouse 
in which the local isoform of IGF-1 (mIGF-1) is driven 
by MLC promoter (MLC/mIGF-1) [17]. The MLC 
regulatory elements included in this construct activate 
linked gene expression as early as E9.5 days in 
embryonic mouse development, and expression 
continues to be high in the fastest Type IIb fibers. 
Transgenic animals exhibits marked skeletal muscle 
hypertrophy with no undesirable side effects such as 
tumor formation.  
 
The increased muscle mass in mIGF-1 transgenic mice 
was associated with augmented force generation 
compared to age-matched wild type littermates [17]. 
Examination of two year-old animals revealed that 
whereas wild type mice underwent characteristic muscle 
atrophy, expression of the mIGF-1 transgene was 
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senescence [17]. Over-expression of the mIGF-1 
transgene also preserved the regenerative capacity of 
senescent muscle tissues stimulating both the activity of 
satellite cells and the recruitment of circulating stem 
cells [17, 18] (Figure 2). We demonstrated that upon 
muscle injury, stem cells expressing c-Kit, Sca-1, and 
CD45 antigens increased locally and the percentage of 
the recruited cells were conspicuously enhanced by 
mIGF-1 expression [18]. More recently, we demon-
strated that local expression of mIGF-1 accelerates the 
regenerative process of injured skeletal muscle, 
negatively modulating the inflammatory response [19]. 
These data indicate that  mIGF-1 promote a qualitative 
environment, guaranteeing a more efficient muscle 
regeneration process. Thus mIGF-1 can overcome the 
normal inability of skeletal muscle to sustain 
regeneration and repair and as such represents a 
potentially effective gene therapeutic strategy to combat 




































demonstration that the action of mIGF-1 is not 
dependent on life-long expression. Introduction of 
mIGF-1 somatically using an Adeno-Associated-Viral 
(AAV) vector was sufficient to rejuvenate the leg 
muscles of 27 month old mice, which exhibited the 
same mechanical force as legs of younger mice, and did 
not develop the pathological characteristics of senescent 
muscle [20].  
 
The importance of appropriate IGF-1 isoform selection 
is further underscored by preliminary analysis of mouse 
lines generated with a second IGF-1 transgene (cIGF-1), 
which differs from the mIGF-1 only in a variant C-
terminal peptide. These animals did not display 
pronounced muscle hypertrophy but had increased 
levels of circulating IGF-1, mild cardiac hypertrophy, 
an increased incidence of late onset neoplasia 
(unpublished observation). Thus, the choice of isoform 










































supplemental  mIGF‐1  creates  a  qualitatively  different  environment  for  sustaining  more  efficient  muscle
regeneration and repair. 
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Muscular dystrophies are degenerative disorders 
characterized by progressive weakness in specific 
muscle groups, persistent protein degradation and 
alteration in the regenerative capacity of muscle satellite 
cells [21]. Mutations in genes encoding proteins of the 
dystrophin-glycoprotein complex (DGC) lead to 
alteration in muscle structure and cause muscular 
dystrophy [21, 22]. Without dystrophin, the DGC is 
unstable leading to an increase in muscle damage. 
Different studies support the notion that loss of the link 
between extracellular matrix and cytoskeleton 
represents the critical parameter for the maintenance of 
the structural integrity of skeletal muscle [23]. 
 
A further complication that exacerbates muscular 
dystrophy is the persistence of inflammation. In normal 
skeletal muscle, damage is followed by an inflammatory 
response [24] involving multiple cell types that subsides 
after several days. This transient inflammatory response 
is a normal homeostatic reaction to myonecrosis and is 
necessary for efficient repair. However a persistent 
inflammatory response is observed in dystrophic 
muscle, leading to an altered extracellular environment 
[25], including an increased presence of inflammatory 
cells (e.g., macrophages) and elevated levels of various 
inflammatory cytokines (e.g., TNF-alpha, TGF-beta).  
 
Because it is clear that mIGF-1 can prevent aging- 
related loss of muscle function, stimulates muscle 
regeneration and modulates the inflammatory response 
in damaged muscle, it is possible that mIGF-1 can 
prevent or diminish muscle loss associated with 
diseases.  
 
To prove this hypothesis, we introduced mIGF-1 into 
the mdx dystrophic animals (mdx/mIGF-1) [26]. By 
analyzing muscle morphology and function in 
transgenic mdx/mIGF-1 mice we observed significant 
improvement in muscle mass and strength, a decrease in 
myonecrosis, and a reduction in fibrosis in aged 
diaphragms [26]. In particular, even though IGF-1 has 
been shown to stimulate fibroblasts, there was a net 
decrease in fibrosis in diaphragms of the mdx/mIGF-1 
mice [26]. It may be that the efficient and rapid repair of 
the mdx/mIGF-1 muscles prevents the establishment of 
an environment into which the fibroblasts migrate. This 
is of particular relevance to the human dystrophic 
condition where virtually all skeletal muscles succumb 
to fibrosis. 
 
Finally, signaling pathways associated with muscle 
regeneration and protection against apoptosis were 
significantly elevated [26]. These results suggest that a 
combination of promoting muscle regenerative capacity 
and preventing muscle necrosis could be an effective 
treatment for the secondary symptoms caused by the 
primary loss of dystrophin. 
 
In addition, another study demonstrated that co-
injection of the rAAV-microdystrophin and rAAV-
mIGF-1 vectors resulted in increased muscle mass and 
strength, reduced myofiber degeneration, and increased 
protection against contraction-induced injury [27]. 
These results suggest that a dual-gene combinatorial 
strategy could enhance the efficacy of gene therapy of 
DMD and underscored the importance of rAAV vectors 
due to their relative lack of immunologic and toxic side 
effect combined with their potential for body-wide 
systemic gene delivery to muscle [27]. 
 
mIGF-1 and Amyotrophic lateral sclerosis (ALS) 
ALS is a progressive, lethal neuromuscular disease 
associated with the degeneration of motor neurons, 
leading to muscle atrophy and paralysis [28]. Although 
a significant proportion of familial ALS results from a 
toxic gain –of function associated with dominant SOD1 
mutations, the etiology of the disease and its specific 
cellular origins have remained difficult to define. 
 
Notably, restriction of SOD1 mutant expression 
selectively to post-natal motor neurons failed to produce 
detectable sign of pathology or motor-neuron disease 
[29], suggesting that other cell types may be involved in 
ALS-associated neurodegeneration. Indeed, analysis of 
chimeras generated between wild type and SOD1 
mutant mouse embryonic cells revealed that wild type 
non neuronal cells in adult chimeric animals extended 
the survival of SOD1 mutant motor neurons, suggesting 
that the neurodegenerative action of mutant SOD1 may 
operate through a dominant paracrine activity 
emanating from non neuronal cells [30].  
 
Skeletal muscle is an untested component in the motor 
neurodegenerative effects of SOD1 mutations. More 
recently, we addressed this critical aspect of the 
pathogenesis of ALS, demonstrating that skeletal 
muscle is a direct target of SOD1
G93A-mediated toxicity 
[31], refocusing therapeutic strategies to attenuate 
motor neuronal degradation towards skeletal muscle. 
 
Adult muscle fibers are a source of signals that 
influence neuron survival, axonal growth and 
maintenance of synaptic connections. Among them 
IGF-1 has also been implicated in anabolism of nerve 
tissue, promoting neuronal survival [7]. 
 
Recently, the potential beneficial effect of human 
recombinant IGF-1 on ALS patients has been tested, 
however the results were doubtful [32]. In particular, 
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beneficial effects in ALS patients [32]. The critical 
problem could be the failure to deliver the neurothophin 
effectively to the target cells and tissue. Moreover, the 
IGF-1 system, as discussed above, is complex, since 
multiple transcripts of the IGF-1 gene encode different 
isoforms, which induce different cellular responses. 
This hypothesis was supported by the evidences that 
either AAV-mIGF-1 mediated muscle delivery [33] or 
localized expression of co-inherited MLC/mIGF-1 
transgene exclusively in the muscles of SOD1
G93A 
mouse [34, 35] counteracts the symptoms of ALS and 
reduces components of catabolism, activating satellite 
cell and markers of regeneration [33-35]. The protective 
effects of muscle-restricted mIGF-1 against the 
dominant action of mutant SOD1
G93A stabilized also 
neuromuscular junctions and led to a reduction in 
astrocytosis/inflammation in the spinal cord, enhancing 




These preliminary studies provide exciting avenues for 
future discovery, however true innovation in this field 
will undoubtedly derive from the integration of our 
insights with other key advances in regenerative 
research, to form a cohesive and coherent strategy that 
addresses the short, medium and long-term aspects of 
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